Chonluten
A synthetic tripeptide bioregulator (Glu-Asp-Gly) from the Khavinson system, studied for respiratory and bronchial mucosal health, anti-inflammatory gene regulation, and stress protection in lung tissue.
What is Chonluten?
Chonluten is a synthetic tripeptide consisting of glutamic acid, aspartic acid, and glycine (Glu-Asp-Gly), developed as part of Vladimir Khavinson's bioregulator peptide system at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as a Cytogen — a lab-synthesized short peptide designed to mirror the regulatory effects of peptides naturally found in bronchial and lung tissue. Its principal biological target is the respiratory system, specifically the bronchial mucosa and lung epithelium. It is often discussed alongside Bronchogen (AEDL), which targets deeper lung tissue and cell differentiation, while Chonluten is more associated with stress-protective and anti-inflammatory gene regulation in respiratory epithelium.
What Chonluten Is Investigated For
Chonluten is a Khavinson-program tripeptide investigated for bronchial and respiratory mucosal health, anti-inflammatory gene regulation in lung tissue, adjunct support for chronic bronchitis and COPD, and stress protection under low-oxygen conditions. The strongest mechanistic evidence is from peer-reviewed in vitro studies in THP-1 monocytes showing that the Glu-Asp-Gly sequence inhibits TNF production and acts as a natural inducer of TNF tolerance under LPS stimulation, plus molecular docking work supporting LAT1 transporter-mediated cellular uptake. The central honest caveat is that clinical evidence is thin and doubly confounded: the Russian clinical literature in chronic bronchitis with asthmatic component uses Chonluten in combination with Bronchogen, making peptide-specific attribution impossible, and no randomized controlled trials are indexed in Western databases. Independent Western replication of the gene-regulation claims is absent, and the proposed mechanism of direct DNA interaction by a tripeptide remains debated. Chonluten is not FDA-approved, not a dietary-supplement ingredient, and should not substitute for evidence-based management of COPD, asthma, or chronic bronchitis.
History & Discovery
Chonluten emerged from the same Khavinson program at the St. Petersburg Institute of Bioregulation and Gerontology that produced the broader Cytogen / Cytomax bioregulator series. It was developed as a synthetic short-peptide counterpart to bronchial-tissue extracts, with the active sequence reduced to the tripeptide Glu-Asp-Gly (EDG, also designated T-34 in some Khavinson-group publications). Within the bioregulator framework it is positioned alongside Bronchogen (AEDL, a tetrapeptide), with Bronchogen aimed at deep lung epithelial differentiation and Chonluten aimed more at stress-protective and anti-inflammatory gene programs in bronchial mucosa. Chonluten's published footprint is real but small: a handful of in vitro studies in monocyte/macrophage models showing TNF and IL-6 suppression, molecular docking work supporting LAT1 transporter-mediated cellular uptake, and a Russian-language clinical literature on chronic bronchitis and asthmatic-component bronchitis where it is typically used in combination with Bronchogen — making peptide-specific attribution difficult. As with the rest of the Khavinson lineup, the work is concentrated within a single research orbit, has not been independently replicated in Western laboratories, and has not generated controlled clinical trial data for any defined respiratory indication.
How It Works
Chonluten is a tiny three-amino-acid peptide proposed to enter lung and bronchial cells, where it helps regulate genes involved in stress defense and inflammation. It may help the respiratory system manage oxidative stress and inflammatory responses by boosting protective gene programs — particularly those encoding antioxidant enzymes and heat-shock proteins.
Chonluten (Glu-Asp-Gly) is proposed to penetrate cell membranes due to its small molecular size and interact with DNA regulatory regions in respiratory epithelial cells. Molecular modeling suggests high affinity for the LAT1 amino acid transporter (ICM-Score: -30.30), providing a plausible cellular uptake mechanism. In vitro studies from the Khavinson group report that the EDG tripeptide modulates expression of stress-response genes including c-Fos and the heat-shock protein gene HSP70, antioxidant enzyme genes (SOD), the inflammatory mediator COX-2, and the cytokine TNF-alpha. In monocyte/macrophage cell line studies, Chonluten inhibited TNF production in LPS-stimulated cells, acting as a natural inducer of TNF tolerance. It also reduced monocyte adhesion to activated endothelial cells and suppressed IL-6 expression, suggesting broad anti-inflammatory signaling effects relevant to bronchopulmonary pathology.
Evidence Snapshot
Human Clinical Evidence
Very limited. Observational clinical data from the Khavinson program suggests oral Chonluten enhanced the effectiveness of standard therapy in patients with chronic bronchitis with an asthmatic component and improved physical performance under low-oxygen conditions. However, these studies used Chonluten in combination with Bronchogen, making individual attribution impossible. No randomized controlled trials are indexed in Western databases.
Animal / Preclinical
Moderate within the Khavinson framework. In vitro monocyte/macrophage studies demonstrate TNF and IL-6 suppression under LPS stimulation. Gene expression studies show regulation of stress-response (c-Fos, HSP70), antioxidant (SOD), and inflammatory (COX-2, TNF-alpha) pathways. Molecular modeling confirms LAT1 transporter binding for cellular uptake.
Mechanistic Rationale
Moderate. The anti-inflammatory effects (TNF tolerance, IL-6 suppression) have been demonstrated in peer-reviewed in vitro studies. The proposed mechanism of respiratory-specific gene regulation through direct DNA interaction is supported by the broader Khavinson short-peptide research program, but has not been independently replicated outside that group.
Research Gaps & Open Questions
What the current literature has not yet settled about Chonluten:
- 01Independent replication outside the Khavinson research program — the in vitro TNF/IL-6 suppression and the proposed bronchial-epithelial gene regulation have not been verified by Western respiratory-immunology laboratories.
- 02Peptide-specific clinical trials — the published Russian clinical literature uses Chonluten in combination with Bronchogen, so there are essentially no monotherapy efficacy data even in the originating program.
- 03Human pharmacokinetics — oral, sublingual, and parenteral bioavailability of the EDG tripeptide in humans is uncharacterized, and the LAT1 transporter binding hypothesis has not been validated in vivo.
- 04Blinded randomized controlled trials in COPD or chronic bronchitis — the existing Russian clinical reports do not meet modern RCT-methodology standards and lack independent replication.
- 05Long-term safety in inflammatory lung disease — chronic anti-inflammatory gene modulation in respiratory epithelium has not been studied for off-target effects.
- 06Comparative efficacy versus first-line respiratory pharmacotherapy — no head-to-head studies against inhaled corticosteroids, LABA/LAMA combinations, or biologics exist.
Forms & Administration
Chonluten is available as oral capsules and sublingual drops. Capsule protocols typically involve 1-2 capsules daily for 10-30 days, with courses repeated 2-3 times per year. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Khavinson-line oral capsules contain on the order of 200 mcg of peptide per capsule, dosed as 1–2 capsules per day. Sublingual drop formulations are also sold and dosed in comparable cumulative ranges. Injectable Chonluten via research-chemical channels, where used, follows the standard bioregulator convention of 100–200 mcg subcutaneously per dose.
Frequency
Once daily during a course is the standard cadence, occasionally split into morning and evening for the oral capsule and drop formulations.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
10-day courses repeated 2–3 times per year is the canonical Khavinson schedule. Some bronchopulmonary protocols extend a single course to 20–30 days. Continuous chronic dosing is not part of the published convention.
Protocol Notes
Chonluten is overwhelmingly an oral and sublingual product in commercial reality, sold under the Khavinson Peptides brand in Russia as a respiratory-support functional food. The published Russian clinical experience layers Chonluten with Bronchogen, so even where some clinical signal exists, separating the contribution of the EDG tripeptide from the AEDL tetrapeptide is not straightforward. Reconstitution for the rare injectable form follows the standard bioregulator convention: 5 mg of lyophilized peptide into 1–2 mL of bacteriostatic water, dosed on an insulin syringe. No Western clinician operates a Chonluten protocol for COPD, chronic bronchitis, or any other respiratory condition; any cadence you encounter outside Russia is forum or vendor convention rather than independently anchored guidance.
Chonluten is not FDA-approved for any indication. Respiratory and anti-inflammatory claims significantly exceed what controlled clinical evidence supports. It should not substitute for evidence-based management of COPD, asthma, chronic bronchitis, or any other pulmonary condition by a qualified clinician.
Timeline of Effects
Onset
No characterized onset profile from controlled clinical work. The proposed mechanism (transcriptional modulation of stress-response and anti-inflammatory gene programs) is structural and slow in concept, not acutely symptomatic. Russian clinical reports measure outcomes at the end of a course rather than tracking acute onset.
Peak Effect
Khavinson protocols measure outcomes at the end of a 10–20 day course. Improvements in physical performance under low-oxygen conditions and in chronic-bronchitis symptom scores have been described at end-of-course assessments, though always in combination with Bronchogen.
After Discontinuation
No documented withdrawal or rebound. The framework's standard claim is gene-expression remodeling persisting after dosing ends, but for Chonluten specifically this persistence has not been independently verified.
Common Questions
Who Chonluten Is NOT For
- •Active or recent malignancy involving lung or bronchial tissue — gene-modulating peptides have not been characterized for safety in pulmonary oncology contexts.
- •Acute respiratory infection requiring evaluation — Chonluten should not delay or substitute for antibiotics, antivirals, or other indicated acute care.
- •Pregnancy — no reproductive-toxicology data; not recommended.
- •Breastfeeding — no data on transfer or infant exposure.
- •Pediatric use — no pediatric safety or developmental data; pulmonary developmental signaling effects unknown.
- •Known hypersensitivity to peptide preparations or to capsule and sublingual-drop excipients in commercial Khavinson-line products.
Drug & Supplement Interactions
There are no documented clinical drug interactions for Chonluten because no human pharmacovigilance studies of meaningful scale exist. What follows is theoretical. The most plausible concerns are with corticosteroids and other anti-inflammatory regimens used in COPD and asthma management. Chonluten's claimed suppression of TNF, IL-6, and COX-2 signaling could in theory layer additively or in unpredictable ways onto inhaled or systemic corticosteroids, leukotriene modifiers, or biologics targeting Th2 inflammation — none of which has been formally studied. A second concern applies to immunosuppressed patients on transplant or autoimmune-disease regimens, where any agent claimed to broadly modulate inflammatory gene expression could, in principle, complicate immunosuppression management. No CYP-mediated interactions are described, and at the small doses involved, pharmacokinetic interactions at the metabolism level are unlikely. Patients on respiratory or immunosuppressive medications should disclose Chonluten use to their prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved
- • Clinical data is limited and primarily from Russian research
- • No formal toxicology or pharmacokinetic studies meeting Western regulatory standards
- • No drug interaction studies have been conducted
- • Quality and purity vary by source
What We Don't Know
Western clinical trial data is absent. No dose-escalation studies, formal toxicology, or independent pharmacokinetic data exist. The claimed mechanism of direct DNA interaction by a tripeptide remains debated in the broader scientific community. Long-term safety has not been evaluated in controlled studies.
Legal Status
United States
Not FDA-approved for any indication. Not recognized as a dietary supplement ingredient and not on the FDA's compounding-eligible peptide list. Available primarily as personally imported Russian-market oral product or via research-chemical injectable channels, neither of which is an authorized clinical pathway.
International
Sold in Russia under the Peptides.ru / Khavinson Peptides brand as an oral peptide bioregulator capsule and sublingual drop, positioned as a dietary supplement / functional food rather than a registered prescription medicine. Not authorized as a medicine by EMA, MHRA, TGA, or Health Canada.
Sports & Competition
Not specifically named on the WADA Prohibited List. Because no governmental regulatory health authority approves Chonluten for human therapeutic use, injectable Chonluten can reasonably be read as falling under WADA's S0 catch-all category. Athletes subject to WADA code should treat injectable Chonluten as prohibited.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Chonluten is a treatment for COPD.
Reality
It is not approved as a treatment for COPD by any regulatory body and there are no controlled trials supporting it as a COPD therapy. Russian clinical literature describes it as an adjunct used alongside Bronchogen and standard care in chronic bronchitis with asthmatic component, which is far short of demonstrating it treats COPD.
Myth
Chonluten and Bronchogen are interchangeable.
Reality
The Khavinson framework explicitly distinguishes them — EDG (Chonluten) for stress-protective and anti-inflammatory gene regulation in bronchial mucosa, AEDL (Bronchogen) for deeper lung epithelial differentiation. Whether that distinction holds biologically is itself a research gap, but they are not marketed or used as substitutes for one another.
Myth
Because Chonluten is small enough for oral and sublingual absorption, the systemic exposure is essentially the same as injection.
Reality
Oral, sublingual, and parenteral bioavailability of EDG have not been measured comparatively in humans. Tripeptides may resist intestinal degradation, but resistance to degradation is not the same as quantified systemic exposure to lung tissue.
Myth
The in vitro TNF and IL-6 suppression translates directly to clinically meaningful anti-inflammatory effect in the lungs.
Reality
Cell-line experiments in THP-1 monocytes are mechanistically informative but routinely fail to predict clinical anti-inflammatory benefit at achievable in vivo concentrations. No bronchoalveolar lavage or pulmonary biomarker data in humans supports the in vitro signal translating to clinical effect.
Published Research
6 studiesTransport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers
Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Demonstrated that Chonluten (EDG) inhibits TNF production in LPS-stimulated monocytes and acts as a natural inducer of TNF tolerance.
Peptide Regulation of Gene Expression: A Systematic Review
Peptides: Prospects for Use in the Treatment of COVID-19
Reviews EDG tripeptide effectiveness for bronchopulmonary pathology and its stress-protective gene regulation (c-Fos, HSP70, SOD, COX-2, TNF-alpha).
Short Peptides Regulate Gene Expression
Peptide regulation of gene expression and protein synthesis in bronchial epithelium
Quick Facts
- Class
- Bioregulator Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Apr 2026
- Citations
- 6PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.